December 4, 2015 /
First data from Phase 2a study of RedHill Biopharma’s RHB-104 expected in early 2016
RedHill
Biopharma, Ltd., recently announced the conclusion of the last dosing and
patient follow-up visit for its Phase 2a proof-of-concept study to assess the
efficacy and safety of the experimental drug RHB-104 as an add-on therapy to
interferon beta-1a in patients with relapsing-remitting multiple sclerosis
(RRMS). MS is a demyelinating disease in which the insulating covers […]
Biopharma, Ltd., recently announced the conclusion of the last dosing and
patient follow-up visit for its Phase 2a proof-of-concept study to assess the
efficacy and safety of the experimental drug RHB-104 as an add-on therapy to
interferon beta-1a in patients with relapsing-remitting multiple sclerosis
(RRMS). MS is a demyelinating disease in which the insulating covers […]
The post RRMS Clinical Study of New Antibiotic Therapy Nearing End
appeared first on Multiple Sclerosis News Today.
appeared first on Multiple Sclerosis News Today.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
